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On the 1860s, Nikolaus Friedreich, a German neurologist 
described a mysterious inherited disease marked by progressive 
loss of coordination and neuronal degeneration, and coined the 
term Friedreich’s ataxia (FRDA). The prevalence of the most 
common hereditary ataxia was estimated at 1 in 29 000, with 
a carrier frequency of 1 in 85 in the individuals of Caucasian 
descent (Delatycki & Corben, 2012; Koeppen, 2013). FRDA is 
known to be a debilitating, life-shortening and degenerative 
neuromuscular disorder where the patients suffer from 
progressive gait and limb ataxia, lack of tendon reflexes in the 
legs, dysarthria, slurred speech and pyramidal weakness of lower 
limbs. The non-neurological symptoms include hypertrophic 
cardiomyopathy, scoliosis, diabetes mellitus or skeletal deformities 
(Delatycki & Corben, 2012).
The pathogenic mutation in FRDA is caused by expansion 
of guanine-adenine-adenine (GAA) trinucleotide repeat in the 
first intron of the frataxin gene on chromosome 9q13-21 that 
leads to a substantial decrease of mitochondrial protein frataxin 
(Jauslin et al., 2007). Reduced frataxin level causes an increase 
of cellular oxidative damage and impaired formation of 
iron-sulfur (Fe-S) clusters such as heme, electron transport chain 
(ETC) complexes O-OOO and the Kreb’s cycle protein aconitase 
(Lodi et al., 2006).
On recent years, culinary and medicinal mushrooms are 
gaining considerable attention for potentials in promoting 
neuronal health. Dne such mushroom, Hericium erinaceus 
(Bull.I:Fr.) Pers. or lion’s mane mushroom is increasingly 
studied for its neuroprotective effects. Ot is one of the culinary 
and medicinal mushrooms found in Asia, Europe and North 
America (Wong et al., 2011).
Hericium erinaceus has been extensively tested in in vitro 
trials as the neurite outgrowth stimulator in the cultured cells 
of neural hybrid clone NG108-15 and rat pheochromocytoma 
(Wong et al., 2007). We also explored its ability in the enhancement 
of peripheral nerve regeneration and acceleration of motor and 
sensory functional recovery after crush injury (Wong et al., 2011, 
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Abstract
Friedreich’s ataxia (FRDA) is a progressive neuromuscular disorder caused by substantial decrease of mitochondrial protein 
frataxin responsible for biogenesis of iron-sulphur clusters and protection from oxidative damage. On this study, we investigated 
the antioxidant activities of a standardized aqueous extract from fruiting bodies of Hericium erinaceus mushroom (HESAE) and 
its protective effects against oxidative damage induced by L-Buthionine sulfoximine (BSD) in fibroblasts derived from FRDA 
patient. The lactate dehydrogenase-based viability assay showed that FRDA fibroblast was sensitive to 12.5 mM BSD with a 
reduction of viability to 52.51 ± 13.92% after 24 h of BSD exposure. Onterestingly, co-incubation with 32 mg/mL HESAE increased 
the viability to 85.35 ± 3.4%. Further, 12.5 mM BSD caused a decrease in the ratio of cellular reduced glutathione (GSH) to 
oxidised GSH (GSSG) that leads to cell death. Nevertheless, the damage was reduced by co-incubation with 32 mg/mL HESAE. 
Nuclear fluorescence staining revealed that 12.5 mM BSD induced cell death and the apoptosis was decreased by co-incubation 
with HESAE. These findings suggest the ability of HESAE in attenuating BSD-mediated cytotoxicity through maintenance of 
membrane integrity and optimal GSH/GSSG ratio, that are closely linked to its antioxidant activities. Further in vivo trials are 
highly warranted to clarify its potential benefits in management of FRDA.
Keywords: Hericium erinaceus; Friedreich’s ataxia; dermal fibroblasts; antioxidant; oxidative damage.
Practical Application: A standardized aqueous extract of Hericium erinaceus is beneficial in attenuating BSD-mediated oxidative 
damage in fibroblasts from Friedreich’s ataxia patient. The medicinal mushroom acts as a potent protector against oxidative 
damage-induced cell death and could be a possible therapeutic for delaying the FRDA symptoms. The observed effects were 
better than idebenone, a lipid antioxidant that has mild adverse effects. Further, the cellular model is an important tool for the 
discovery of novel therapeutic approach in FRDA in which reactive radicals and oxidative damage are involved.
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2015). Onanaga (2014) reported an improved neurocognitive 
function in an 86-year-old male patient with recurrent depressive 
disorder while Dkamura et al. (2015) reported improved sleep 
quality and subjective well-being among female undergraduate 
students after taking the mushroom tablets, Amyloban 3399. 
On a study by Nagano et al. (2010), H. erinaceus cookies was 
shown to reduce depression and anxiety in 30 females between 
age 40-45. The broad therapeutic benefits of H. erinaceus may 
be associated to its strong antioxidant effects (Friedman, 2015). 
Therefore, the potential of H. erinaceus in combating oxidative 
damage-related neurodegenerative diseases including hereditary 
ataxia could be explained by the neuroprotective activity and 
its plentiful source of exogenous antioxidants.
This prompted our interest to investigate the protective 
effects of a standardized aqueous extract from fruiting bodies 
of H. erinaceus (HESAE) against oxidative damage induced by 
L-Buthionine sulfoximine (BSD) in fibroblasts from a FRDA 
patient and to link the effectiveness to its antioxidant properties. 
To the best of our knowledge, there are no reports on therapeutic 
application of medicinal mushrooms in FRDA. HESAE is a 
dietary supplement manufactured in Malaysia that targets on 
the general health maintenance. BSD is a specific inhibitor of 
γ-glutamylcysteine synthetase and its downregulation results 
in reduction of mitochondrial glutathione, increased oxidative 
damage and decreased mitochondrial function (Reliene & 
Schiestl, 2006).
2 Materials and methods
2.1 Mushroom sample
The aqueous extract of H. erinaceus (HESAE; NevGro; batch 
No. 7H2308X) was obtained from Ganofarm R&D Private Limited, 
Tanjung Sepat, Selangor, Malaysia. NevGro is a standardized 
aqueous extract from fresh fruiting bodies of H. erinaceus that 
contains not less than 20.66% beta 1,3-1,6 glucan and 0.17% 
adenosine (Nova Laboratories Private Limited, Sepang, Selangor, 
Malaysia). Total glucan and α-glucan were determined by the 
β-glucan assay kit (yeast & mushroom) K-YBGL (Megazyme 
Onternational, Wicklow, Oreland). The β-glucan content was 
calculated by subtracting the α-glucan from the total glucan 
content. Adenosine content was analyzed and quantified by 
high-performance liquid chromatography (HPLC) using an 
in-house method (Nova Laboratories Private Limited, Sepang, 
Selangor, Malaysia). A stock solution of 64 mg/mL was prepared 
by dissolving HESAE in distilled water for the assessment of 
phytochemical contents and in vitro antioxidant activities or in 
phenol red-free Dulbecco’s Modified Eagle Medium (DMEM) 
and filter sterilized through a 0.2 μm nylon membrane filter for 
the measurement of oxidative damage.
2.2 Determination of total phenolic content
The concentration of phenolic compounds in HESAE and 
idebenone (Cayman Chemical, Ann Arbor, MO, USA), expressed 
as gallic acid equivalent (GAE), was determined according to a 
method as described by Singleton et al. (1999) and Pang et al. 
(2018).
2.3 Determination of total flavonoid content
The concentration of flavonoid compounds in HESAE 
and idebenone, expressed as quercetin equivalent (QE), was 
determined according to a method as described by Pękal & 
Pyrzynska (2014) and Pang et al. (2018).
2.4 DPPH free radical scavenging assay
The scavenging activity of HESAE on 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical was measured according to the 
method of Brand-Williams et al. (1995). Odebenone was used as a 
positive control. The scavenging ability of HESAE was expressed 
as EC50 value (mg/mL), which is the effective concentration at 
which 50% of DPPH radicals were scavenged.
2.5 ABTS free radical scavenging assay
The scavenging activity of HESAE on 2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical 
was measured according to the method of Miller et al. (1993). 
Odebenone was used as a positive control. The scavenging ability 
of HESAE was expressed as EC50 value (mg/mL), which is the 
effective concentration at which 50% of ABTS radicals were 
scavenged.
2.6 Reducing power assay
Reducing power of HESAE was determined according to 
the method of Dyaizu (1986). Odebenone was used as a positive 
control. The reducing power of HESAE was expressed as EC50 
value (mg/mL), at which the absorbance was 0.5.
2.7 Dermal fibroblasts culture
Dermal fibroblasts from a 30-year-old FRDA male patient 
(GM04078) and dermal fibroblasts from a healthy 11-year-old 
female (GM02036) were purchased from Coriell Onstitute 
(Camden, NJ, USA). The fibroblasts were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 15% fetal 
bovine serum and 1% penicillin-streptomycin at 37 ± 2 °C in a 5% 
CD2-humidified incubator. Prior to L-Buthionine sulfoximine 
(BSD), BSD-HESAE or BSD-idebenone treatment, the medium 
was changed to phenol red- and sodium pyruvate-free DMEM 
containing 1% fetal bovine serum and 1% penicillin-streptomycin. 
Fibroblasts treated with 5 μM of idebenone served as a positive 
control (Jauslin et al., 2002), while fibroblasts in complete DMEM 
without treatment served as a negative control.
2.8 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) viability assay
MTT assay was used to assess the effect of BSD or HESAE 
on viability of normal and FRDA fibroblasts. Fibroblasts were 
plated at a density of 5 × 103 cells per well in 96-well plates and 
incubated for 24 h at 37 ± 2 °C in a 5% CD2-humidified incubator. 
Then, the medium was replaced with fresh medium containing 
BSD or HESAE. After 24 h of incubation, the morphology 
of fibroblasts was acquired on Nikon Eclipse Ti-S inverted 
microscope equipped with a digital camera controller (DS-U3) 
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Food Sci. Technol, Campinas,    Ahead of Print, 2019 3/9   3
and NOS-Elements algorithm (NOS-Elements Advanced Research, 
Nikon Corporation, Tokyo, Japan). The extent of MTT reduction 
was determined by measuring the absorbance at 570 nm with 
630 nm as background absorbance in a multimode microplate 
reader (SpectraMax M3, Molecular Devices, San Jose, CA, USA). 
The fibroblasts in complete DMEM without treatment served 
as a negative control. The 50% inhibitory concentration (OC50) 
was interpolated from the response curve.
2.9 Lactate dehydrogenase (LDH) viability assay
LDH assay was used to determine the protective effect of 
HESAE against BSD-induced cytotoxicity in FRDA fibroblasts 
based on the measurement of LDH released from the cytosol of 
damaged fibroblasts into the supernatant. The fibroblasts were 
plated at a density of 5 × 103 cells per well in 96-well plates and 
incubated for 24 h at 37 ± 2 °C in a 5% CD2-humidified incubator. 
The medium was replaced with fresh medium containing BSD, 
BSD-HESAE or BSD-idebenone and incubated for another 
24 hr. Fibroblasts treated with 5 μM of idebenone served as a 
positive control while fibroblasts in complete DMEM without 
treatment served as a negative control. After incubation, the 
plate was centrifuged at 1500 rpm for 5 min at 18 °C. Culture 
supernatant was subjected to LDH measurement according to 
the manufacturer’s protocol of LDH cytotoxicity detection kit 
(Roche, Mannheim, Germany). LDH activity was determined by 
measuring the absorbance at 492 nm with 690 nm as background 
absorbance in a multimode microplate reader (SpectraMax M3, 
Molecular Devices, San Jose, CA, USA).
2.10 Reduced glutathione/oxidized glutathione (GSH/GSSG) 
assay
GSH/GSSG assay is a luminescence-based system for the 
detection and quantification of total glutathione and oxidised 
glutathione (GSSG) in cultured cells. The ratio of reduced 
glutathione (GSH) to oxidised GSH (GSSG) is an indicator of 
cellular health, with reduced GSH making up to 98% of cellular 
GSH under normal conditions. Fibroblasts were plated at a 
density of 5 × 103 cells per well in white opaque 96-well plates and 
incubated for 24 h at 37 °C in a 5% CD2-humidified incubator. 
The medium was replaced with fresh medium containing BSD, 
BSD-HESAE or BSD-idebenone and incubated for another 
24 h. Fibroblasts treated with 5 μM of idebenone served as a 
positive control, while fibroblasts in complete DMEM without 
treatment served as a negative control. After incubation, the 
medium was removed and subjected to total glutathione and 
GSSG measurement according to the manufacturer’s protocol 
of GSH/GSSG-Glo glutathione assay kit (Promega Corporation, 
Madison, WO, USA) in a multimode microplate reader (SpectraMax 
M3, Molecular Devices, San Jose, CA, USA).
2.11 Hoechst 33258 staining of apoptotic nuclei
Fibroblasts were plated at a density of 5 × 103 cells per 
well in black 96-well plates and incubated for 24 h at 37 ± 2 °C 
in a 5% CD2-humidified incubator. Then, the medium was 
replaced with fresh medium containing BSD, BSD-HESAE 
or BSD-idebenone. Fibroblasts treated with 5 μM idebenone 
served as a positive control, while fibroblasts in complete 
DMEM without treatment served as a negative control. After 
24 h of incubation, the medium was discarded and loaded with 
5 μg/mL Hoechst 33258 in PBS, further incubated in the dark 
for 10 min and washed twice with PBS. Omages were acquired 
on Nikon Eclipse Ti-S inverted microscope and Ontensilight 
C-HGFO Precentered Fiber Olluminator (Nikon Corporation, 
Tokyo, Japan) at 460 nm. Bright-blue fluorescence indicated 
nuclear apoptosis. OmageJ (National Onstitutes of Health, 2019) 
was used to quantify the blue fluorescence intensity in nine 
randomly chosen microscopic fields (Zhu et al., 2015).
2.12 Statistical analysis
Statistical significance was analyzed with independent 
t-test and one-way ANDVA followed by Tukey’s and Dunnett’s 
multiple comparison tests. Differences with p value less than 
0.05 (p < 0.05) were considered statistically significant.
3 Results
3.1 In vitro antioxidant activities of HESAE
Table  1 shows the phytochemical contents and in vitro 
antioxidant activities of HESAE on DPPH and ABTS free 
radical scavenging, and reducing power assays. The total 
phenolic and flavonoid contents of HESAE were found to be 
7.19 ± 0.6 mg GAE/g and 5.31 ± 0.3 mg QE/g, respectively. 
HESAE exhibited similar levels of total flavonoid content, 
DPPH and ABTS free radical scavenging activities (p > 0.05) 
as compared to idebenone and possessed significantly higher 
total phenolic content (p < 0.05) of 7.19 ± 0.6 mg GAE/g and 
lower EC50 value (p < 0.05) of 58.23 ± 3.9 mg/mL in reducing 
power than idebenone.
Table 1. Phytochemical contents and antioxidant capacity of HESAE and idebenone. Values were represented as mean ± SD of triplicates. Means 
with different alphabets in the same assay were significantly different (p < 0.05).
HESAE / Odebenone Total phenolic content (mg GAE/g)






radical scavenging Reducing power
HESAE 7.19 ± 0.6 a 5.31 ± 0.3 13.22 ± 0.3 14.34 ± 0.9 58.23 ± 3.9a
Idebenone 2.38 ± 0.7 b 4.73 ± 0.5 16.34 ± 4.3 17.74 ± 2.5 120.19 ± 19.99b
HESAE = standardized aqueous extract from fruiting bodies of Hericium erinaceus; EC50 = half-maximal effective concentration; DPPH = 2,2-diphenyl-1-picrylhydrazyl; ABTS = 2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid).
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3.2 Effects of BSO on the viability of normal and FRDA 
fibroblasts
The vulnerability of normal and FRDA fibroblast to oxidative 
damage caused by glutathione depletion was investigated 
through exposure to BSD at varying concentrations ranged 
from 1.56 to 100 mM.
Figure 1 shows morphological features of normal [A(O)-D(O)] 
and FRDA fibroblasts [A(OO)-D(OO)] following incubation in 
BSD for 24 h. At 12.5 and 25 mM BSD, FRDA fibroblast showed 
distinct alteration with floating debris and loss of spindle shape 
[C(OO)-D(OO)]. However, normal fibroblasts retained their typical 
spindle shape at 6.25 and 12.5 mM BSD [B(O)-C(O)]. Figure 1E 
shows the dose-response curve of viability of normal and FRDA 
Figure 1. Morphological features of normal and FRDA fibroblasts following incubation with varying concentrations of L-Buthionine sulfoximine 
(BSD) for 24h. A(O) to D(O) Normal fibroblasts. A(OO) to D(OO) FRDA fibroblasts. A(O) and A(OO) Normal and FRDA fibroblasts in negative 
control group; B(O) and B(OO) Normal and FRDA fibroblasts exposed to 6.25 mM BSD; C(O) and C(OO) Normal and FRDA fibroblasts exposed to 
12.5 mM BSD; D(O) and D(OO) Normal and FRDA fibroblasts exposed to 25 mM BSD. Scale bar = 100 µm; (E) Percentage of viability of normal 
and FRDA fibroblasts following incubation with varying concentrations of BSD for 24 h. Asterisks (*) and hash signs (#) indicate significant 
differences (p < 0.05) in viability for different groups of normal and FRDA fibroblasts, respectively, compared to the negative control group.
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fibroblasts following exposure to varying concentrations of BSD 
for 24 h. All tested concentrations of BSD significantly reduced 
(p < 0.05) the viability of FRDA fibroblasts. The viability of 
FRDA fibroblasts decreased gradually as the concentration of 
BSD increases with a sharp decrease in viability at 12.5 mM BSD. 
Large-scale death of FRDA fibroblasts was markedly pronounced 
by challenging the cells with 12.5 mM BSD in which the viability 
was reduced to 37.47 ± 0.23%. Dn the other hand, 12.5 mM BSD 
produced mild cytotoxicity effects in normal fibroblasts.
As 12.5 mM BSD produced more than 50% reduction 
(p < 0.05) in the viability of FRDA fibroblasts, therefore the 
concentration was selected in the subsequent assays to induce 
oxidative damage in FRDA fibroblasts.
3.3 Effects of HESAE on the viability of normal and FRDA 
fibroblasts
Prior to the investigation of cytoprotective activities, the effects 
of HESAE to the viability of normal and FRDA fibroblasts was 
assessed by MTT assay to exclude any possibilities of cytotoxicity 
effects of the extract. Figure 2 shows that HESAE in the range 
of 1 to 32 mg/mL exerted neither inhibition nor increase in the 
viability of fibroblasts, and therefore was selected for LDH viability 
assay to study its protective effects against 12.5 mM BSD-induced 
cytotoxicity in FRDA fibroblasts. Further, the 50% inhibitory 
concentration of HESAE on normal and FRDA fibroblasts was 
52.26 mg/mL and 46.77 mg/mL, respectively.
3.4 Effects of HESAE on the viability of BSO-treated FRDA 
fibroblasts determined by quantification of LDH
The protective effects of HESAE against BSD-induced 
cytotoxicity in FRDA fibroblasts was investigated by co-incubating 
varying concentrations of HESAE with 12.5 mM BSD. As shown 
in Figure 3, the viability of FRDA fibroblasts was reduced from 
100.00 ± 0.8% to 52.51 ± 13.92% by 12.5 mM BSD (p < 0.05). However, 
co-incubation with 32 mg/mL HESAE significantly increased the 
viability of FRDA fibroblasts to 85.35 ± 3.4% (p < 0.05) that was 2-fold 
higher compared to 5 μM idebenone at 40.09 ± 0.41% (p < 0.05).
Mechanisms of cell death and survival were further examined 
by quantification of glutathione content and induction of apoptosis. 
As 32 mg/mL HESAE promoted highest percentage of viability 
of BSD-induced oxidative damage in FRDA fibroblasts, the 
concentration was selected for subsequent assays.
3.5 Effects of HESAE on the ratio of GSH/GSSG in 
BSO-treated FRDA fibroblast
This reduction in the GSH/GSSG ratio indicates redox 
imbalance and increase in oxidants due to neurodegenerative 
diseases. The GSH/GSSG ratio was determined in FRDA fibroblasts 
following co-incubation of 12.5 mM BSD with 32 mg/mL HESAE 
for 24 h. As shown in Figure 4, BSD significantly depleted the 
GSH/GSSG ratio up to 50-fold compared to negative control 
(p < 0.05), and HESAE appeared to increase the GSH/GSSG ratio 
up to 17-fold and 80-fold, compared to BSD and BSD-idebenone 
groups, respectively (p < 0.05). The data show that HESAE 
prevented BSD from depleting intracellular GSH/GSSG ratio 
or induced glutathione synthesis in vitro.
Figure 2. Effects of HESAE on viability of normal and FRDA fibroblasts 
detected by MTT assay following incubation with varying concentrations 
of HESAE for 24 h. Asterisks (*) and hash signs (#) indicate significant 
differences (p < 0.05) in viability for different groups of normal and 
FRDA fibroblasts, respectively, compared to the negative control group.
Figure 3. Effects of HESAE on viability of FRDA fibroblasts detected 
by LDH assay following co-incubation of 12.5 mM BSD and varying 
concentrations of HESAE for 24 h. Asterisks (*) and hash signs (#) 
indicate significant differences (p < 0.05) in viability for different 
groups compared to the BSD-treated group and BSD-idebenone 
group, respectively.
Figure 4. Effects of HESAE on GSH/GSSG ratio in BSD-treated FRDA 
fibroblasts following co-incubation of 12.5 mM BSD and 32 mg/mL 
HESAE for 24 h. Asterisks (*) and hash signs (#) indicate significant 
differences (p < 0.05) in GSH/GSSG ratio for different groups compared 
to the BSD-treated group and BSD-idebenone group, respectively.
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3.6 Effects of HESAE on nuclear apoptosis in BSO-treated 
FRDA fibroblasts
As shown in Figure 5A-D, nuclei of untreated FRDA fibroblasts 
exhibited homogeneously dim-blue and round shape structure after 
labeling with Hoechst 33258. The introduction of 12.5 mM BSD 
into FRDA fibroblasts causes induction of apoptosis indicated 
by bright-blue fluorescence. However, co-incubation with 5 μM 
idebenone or 32 mg/mL HESAE reduced the fluorescence intensity. 
Figure 5E shows that BSD significantly increased the fluorescence 
intensity from 100.00 ± 8.73% to 121.74 ± 2.04% (p < 0.05). 
The intensity was reduced to 98.74 ± 4.23% (p < 0.05) by co-incubation 
with 32 mg/mL HESAE. Dn the other hand, the intensity 
of 153.41 ± 2.08% was obtained by co-incubation with 5 μM 
idebenone.
4 Discussion
Natural products have been traditionally accepted as 
remedies due to popular belief that they present minor adverse 
effects. There is currently no reports of natural product that 
possesses protective effects in an in vitro model of FRDA. 
This circumstance stimulated our interest to explore HESAE 
and to probe the mechanism underlying the protective effects 
in FRDA.
Phenolic acids that possess hydroxyl groups are the major 
bioactive components in medicinal mushrooms and are also 
associated with their antioxidant properties (Ferreira et al., 2009; 
Heleno et al., 2012). The total phenolic content of HESAE obtained 
from this study was higher compared to that of methanolic 
extracts of fresh fruiting bodies (0.26 mg GAE/g extract), 
Figure 5. FRDA fibroblasts stained as blue fluorescence with Hoechst 33258 for the detection of apoptotic nuclei after 24 h. (A) FRDA fibroblasts 
in negative control group; (B) FRDA fibroblasts exposed to 12.5 mM BSD; (C) FRDA fibroblasts following co-incubation of 12.5 mM BSD and 
5 µM idebenone; (D) FRDA fibroblasts following co-incubation of 12.5 mM BSD and 32 mg/mL HESAE. Scale bar = 100 µm; (E) Ontensity of 
Hoechst 33258 blue fluorescence in the FRDA fibroblasts. Asterisks (*) and hash signs (#) indicate significant differences (p < 0.05) in fluorescence 
intensity for different groups compared to the BSD-treated group and BSD-idebenone group, respectively.
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oxidative damage/dysfunction during aging, multiple chronic 
diseases and cataracts (Lodi et al., 2006). Remarkably, our results 
demonstrated that HESAE increased the ratio compared to BSD 
or co-incubation with idebenone. Nevertheless, our present 
findings are in contrast to Richardson et al. (2012) who reported 
that estrogen-like compounds failed to prevent BSD from causing 
GSH depletion or to increase the expression of GSH.
Figure 6 demonstrates the mechanisms by which BSD promotes 
apoptosis in FRDA fibroblasts and protective effects of HESAE 
against the oxidative damage. As FRDA fibroblasts are lacking 
in frataxin, the cells are extremely sensitive to BSD-induced 
oxidative stress compared to normal fibroblasts. Frataxin has 
been shown to be influential in the production of Fe-S cluster 
containing proteins (Richardson et al., 2012). We postulated that 
synthesis of glutathione in FRDA fibroblasts was greatly diminished 
following incubation in BSD as evidenced by extreme reduction 
in GSH/GSSG ratio up to 50-fold. Disruption in the redox state 
of FRDA fibroblasts resulted in an increase of cytosolic LDH 
causing a 48% reduction in viability that leads to 22% increase 
in apoptosis compared to negative control. Viability of FRDA 
fibroblasts was inhibited by more than half with prominent 
alteration in the morphology. However, HESAE could attenuate 
the cytotoxicity effects through the prevention of glutathione 
depletion, decreasing the level of LDH that reflects the integrity 
of plasma membrane and anti-apoptotic activity. The elevation 
in serum LDH level is a reliable biomarker of FRDA. On a case 
report by Krongrad & Joos (1972), a 7-year-old Caucasian girl 
with FRDA and myocardial infarction had persistent elevation 
of cardiac specific LDH isoenzyme 5.
Antioxidant therapy with idebenone is currently the only 
treatment option resulting in an improvement of hypertrophic 
cardiomyopathy (Jauslin et al., 2007). On our study, idebenone 
did not protect BSD-induced oxidative insult to FRDA fibroblast 
as measured by apoptotic cell death and release of LDH from 
damaged cells owing to membrane disintegration. Several 
studies have also reported conflicting results of idebenone in 
cardiovascular clinical trials of FRDA (Kearney et al., 2016). 
oven-dried fruiting bodies (2.37 mg GAE/g extract), and 
freeze-dried fruiting bodies (0.78 mg GAE/g extract) of 
H. erinaceus (Wong et al., 2009).
On a study by Hou et al. (2015), a purified oligosaccharide 
isolated from H. erinaceus water extract (HED-A) possessed DPPH 
radical scavenging activity at EC50 value of ~12.5 mg/mL which 
was almost similar compared to HESAE at 13.22 ± 0.3 mg/mL 
and an EC50 value of 0.93 mg/mL in ABTS radical scavenging 
activity which was 15-fold higher compared to 14.34 ± 0.9 mg/mL 
exhibited by HESAE. Nevertheless, it has been demonstrated 
that a purified compound may not necessary possess antioxidant 
function compared to its extract counterpart. Ethanol and 
water extracts of H. erinaceus showed more potent reducing 
power and free radical scavenging activities compared to low 
polarity solvents, indicating that antioxidant compounds are 
often concentrated in more polar solvents (Jiang et al., 2016). 
HESAE was prepared by high polarity aqueous extraction of fresh 
fruiting bodies to ensure total extractable phenolic, flavonoid 
and antioxidant contents (Mau et al., 2002; Wong et al., 2009).
Dermal fibroblasts from FRDA patients is a widely accepted 
in vitro model for studying FRDA (Jauslin et al., 2002, 2003). 
The FRDA fibroblasts are homozygous for trinucleotide GAA 
expansion in the frataxin gene with alleles of approximately 
541 and 420 repeats. Functional frataxin is crucial in the production 
of Fe-S cluster containing proteins (Richardson et al., 2012).
Dxidative damage has been shown to be a key element in 
the pathogenesis of FRDA. Onterestingly, we found that FRDA 
fibroblasts were sensitive to BSD-induced oxidative damage at 
12.5 mM compared to normal fibroblasts that required higher 
concentrations of BSD to obtain a comparable toxicity. Glutathione 
is a redox-active molecule existing in the forms of thiol (GSH) 
and disulphide (GSSG). Reduced level of glutathione causes 
irreversible inhibition of γ-glutamylcysteine synthetase, the 
rate-limiting enzyme in the biosynthesis of GSH after exposure 
to BSD. A chronic deficit in the GSH/GSSG ratio is an indicator 
of oxidative stress and renders mitochondria more vulnerable to 
Figure 6. Protective mechanism of HESAE in BSD-exposed FRDA dermal fibroblasts.
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Ebselen, a glutathione peroxidase mimetic (Jauslin et al., 
2002) and a novel synthetic antioxidant (Fe-Aox29) combining 
the active groups from idebenone and vitamin E (Jauslin et al., 
2007) are more potent in preventing BSD-mediated cell death 
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(Richardson et al., 2011), estrogen receptor β agonist of R- and 
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5 Conclusion
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